Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3) (EXETUMOR3)
Primary Purpose
Tumor
Status
Unknown status
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Exercise
Sponsored by
About this trial
This is an interventional basic science trial for Tumor focused on measuring tumor, PET, exercise, blood flow
Eligibility Criteria
Inclusion Criteria:
- a disease of newly diagnosed breast cancer, Hodgkin lymphoma, recurrent Hodgkin lymphoma and non-Hodgkin lymphoma with neck and thorax involvement.
Exclusion Criteria:
- abnormal fatigue, anemia, or physical dysfunction due to the disease
Sites / Locations
- Turku PET CentreRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental arm
Arm Description
Blood flow of the tumor experimented
Outcomes
Primary Outcome Measures
Blood flow
Blood flow measured by PET imaging
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04990856
Brief Title
Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3)
Acronym
EXETUMOR3
Official Title
Tumor Blood Flow After Physical Exercise in Breast Cancer and Lymphoma Patients (Exetumor3 Study)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
August 10, 2021 (Anticipated)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Turku University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Recent pre-clinical studies strongly suggest that due to dysfunctional vasculature and blunted sympathetic constriction in the tumor, tumor blood flow is increased even by 200% compared to resting values. However, to the best of our knowledge these blood flow aspects have never been addressed clinically. Therefore, this research aims at investigating tumor blood flow response to exercise in human cancer patients. To address this goal, in total twenty (20) newly diagnosed breast cancer and eight (8) lymphoma patients will be recruited for the present acute exercise and tumor perfusion clinical trial. To study the effect of acute physical exercise on tumor blood flow and its heterogeneity, 30 minute bicycle exercise will be used to exercise these patients. Tumor blood flow will be measured by positron emission tomography at rest before and after the exercise. If the hypothesis of increased blood flow in response to exercise will be detected, this project has the potential to increase the basic physiological and mechanistic understanding of tumor microvasculature function in humans, which is also clinically highly relevant and can have long-lasting influences in the field in the future. Thus, the results from the project can be a breakthrough for cancer treatment, its mechanistic arguments, and thus renewal of evidence-based medicine and patient care.
Detailed Description
In regards to cancer, it would be reasonable to assume that also cancer behaves like all other inactive tissues in a body during exercise, meaning that also blood flow in the tumor environment is reduced particularly when exercise intensity increases. However, recent pre-clinical studies suggest that due to dysfunctional vasculature and blunted sympathetic constriction in the tumor, tumor blood flow is increased even by 200% compared to resting values (6; 18; 19) as increased cardiac output and blood pressure enhance perfusion pressure in the tumor. This improves its oxygenation (6; 18; 19), which is important as tumor hypoxia negatively affects the efficacy of treatment (27). Tumor hypoxia is promoted by heterogeneous blood flow in the tumor, but according to these pre-clinical studies exercise reduces the heterogeneity of tumor perfusion. However, it is not currently known if this is the case in patients, and it might be that tumor perfusion is actually decreased during exercise, but increased post-exercise, but this has never been addressed in clinical patients and is therefore the aim of the present study. Importantly, advanced imaging methods are available to investigate whether these pre-clinical findings can be extended to humans to serve as an evidence based proof-of-concept for the possible inclusion of exercise in the treatment of cancer during chemotherapy.
OBJECTIVES AND PURPOSE
The most important objective of this directly translatable and highly inter- disciplinary imaging, physical activity, health and medical research in the acute exercise study setting is:
To investigate whether acute moderate intensity exercise increases tumor blood flow
-It is hypothesized and expected that exercise increases tumor blood flow, documented as perfusion increase after acute exercise
STUDY DESIGN Each subject will serve their own control (tumor blood flow at rest vs. blood flow after exercise). Tumor blood flow will be measured with positron emission tomography (PET). To study the effect of acute physical exercise on tumor blood flow and its heterogeneity, bicycle exercise before PET scan will be used to exercise breast cancer and lymphoma cancer patients. These experiments are additional measurements to their normal treatments, and no new interventional approaches will be conducted in this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tumor
Keywords
tumor, PET, exercise, blood flow
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental arm
Arm Type
Experimental
Arm Description
Blood flow of the tumor experimented
Intervention Type
Procedure
Intervention Name(s)
Exercise
Intervention Description
Tumor blood flow after acute exercise
Primary Outcome Measure Information:
Title
Blood flow
Description
Blood flow measured by PET imaging
Time Frame
up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
a disease of newly diagnosed breast cancer, Hodgkin lymphoma, recurrent Hodgkin lymphoma and non-Hodgkin lymphoma with neck and thorax involvement.
Exclusion Criteria:
abnormal fatigue, anemia, or physical dysfunction due to the disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ilkka Heinonen
Phone
+35823138145
Email
ilkka.heinonen@utu.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ilkka Heinonen
Organizational Affiliation
Turku PET Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Turku PET Centre
City
Turku
ZIP/Postal Code
20521
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilkka H Heinonen, PhD
Email
ilkka.heinonen@utu.fi
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
up to 12 months
Learn more about this trial
Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3)
We'll reach out to this number within 24 hrs